This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 93/2/148    most recent 01.RES.0000081593.33848.FCv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Georgiadis, D. Articles by Dive, V. Search for Related Content PubMed PubMed Citation Articles by Georgiadis, D. Articles by Dive, V. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Related Collections ACE/Angiotension receptors

(Circulation Research. 2003;93:148.)
© 2003 American Heart Association, Inc.

Molecular Medicine

Roles of the Two Active Sites of Somatic Angiotensin-Converting Enzyme in the Cleavage of Angiotensin I and Bradykinin

Insights From Selective Inhibitors

Dimitris Georgiadis, Fabrice Beau, Bertrand Czarny, Joël Cotton, Athanasios Yiotakis, Vincent Dive

From the Laboratory of Organic Chemistry (D.G., A.Y.), Department of Chemistry, University of Athens, Panepistimiopolis, Zografou, Athens, Greece; Commissariat à l’Energie Atomique (CEA) (F.B., B.C., J.C., V.D.), Département d’Ingénierie et d’Etudes des Protéines, Gif/Yvette, France.

Correspondence to Dr V. Dive, Commissariat à l’Energie Atomique (CEA), Département d’Ingénierie et d’Etudes des Protéines, 91191 Gif/Yvette, France. E-mail vincent.dive{at}cea.fr

Somatic angiotensin-converting enzyme (ACE) contains two homologous domains, each bearing a functional active site. The in vivo contribution of each active site to the release of angiotensin II (Ang II) and the inactivation of bradykinin (BK) is still unknown. To gain insights into the functional roles of these two active sites, the in vitro and in vivo effects of compounds able to selectively inhibit only one active site of ACE were determined, using radiolabeled Ang I or BK, as physiological substrates of ACE. In vitro studies indicated that a full inhibition of the Ang I and BK cleavage requires a blockade of the two ACE active sites. In contrast, in vivo experiments in mice demonstrated that the selective inhibition of either the N-domain or the C-domain of ACE by these inhibitors prevents the conversion of Ang I to Ang II, while BK protection requires the inhibition of the two ACE active sites. Thus, in vivo, the cleavage of Ang I and BK by ACE appears to obey to different mechanisms. Remarkably, in vivo the conversion of Ang I seems to involve the two active sites of ACE, free of inhibitor. Based on these findings, it might be suggested that the gene duplication of ACE in vertebrates may represent a means for regulating the cleavage of Ang I differently from that of BK.

Key Words: angiotensin-converting enzyme • angiotensin • bradykinin • phosphinic peptide inhibitors

This article has been cited by other articles:

				S. Fuchs, H. D. Xiao, C. Hubert, A. Michaud, D. J. Campbell, J. W. Adams, M. R. Capecchi, P. Corvol, and K. E. Bernstein Angiotensin-Converting Enzyme C-Terminal Catalytic Domain Is the Main Site of Angiotensin I Cleavage In Vivo Hypertension, February 1, 2008; 51(2): 267 - 274. [Abstract] [Full Text] [PDF]

				Z. Chen, F. Tan, E. G. Erdos, and P. A. Deddish Hydrolysis of Angiotensin Peptides by Human Angiotensin I-Converting Enzyme and the Resensitization of B2 Kinin Receptors Hypertension, December 1, 2005; 46(6): 1368 - 1373. [Abstract] [Full Text] [PDF]

				T. Renne, K. Schuh, and W. Muller-Esterl Local Bradykinin Formation Is Controlled by Glycosaminoglycans J. Immunol., September 1, 2005; 175(5): 3377 - 3385. [Abstract] [Full Text] [PDF]

				J. H.M. van Esch, B. Tom, V. Dive, W. W. Batenburg, D. Georgiadis, A. Yiotakis, J. M.G. van Gool, R. J.A. de Bruijn, R. de Vries, and A.H. J. Danser Selective Angiotensin-Converting Enzyme C-Domain Inhibition Is Sufficient to Prevent Angiotensin I-Induced Vasoconstriction Hypertension, January 1, 2005; 45(1): 120 - 125. [Abstract] [Full Text] [PDF]

				H. Katzov, A. M. Bennet, P. Kehoe, B. Wiman, M. Gatz, K. Blennow, B. Lenhard, N. L. Pedersen, U. de Faire, and J. A. Prince A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity Hum. Mol. Genet., November 1, 2004; 13(21): 2647 - 2657. [Abstract] [Full Text] [PDF]

				K. Kohlstedt, R. P. Brandes, W. Muller-Esterl, R. Busse, and I. Fleming Angiotensin-Converting Enzyme Is Involved in Outside-In Signaling in Endothelial Cells Circ. Res., January 9, 2004; 94(1): 60 - 67. [Abstract] [Full Text] [PDF]

				A. G. Tzakos, A. S. Galanis, G. A. Spyroulias, P. Cordopatis, E. Manessi-Zoupa, and I. P. Gerothanassis Structure-function discrimination of the N- and C- catalytic domains of human angiotensin-converting enzyme: implications for Cl- activation and peptide hydrolysis mechanisms Protein Eng. Des. Sel., December 1, 2003; 16(12): 993 - 1003. [Abstract] [Full Text] [PDF]

				A. Husain, M. Li, and R. M. Graham Do Studies With ACE N- and C-Domain-Selective Inhibitors Provide Evidence for a Non-ACE, Non-Chymase Angiotensin II-Forming Pathway? Circ. Res., July 25, 2003; 93(2): 91 - 93. [Full Text] [PDF]